ArticleJCO clinical cancer informatics2026
Leveraging Population-Level and Multipayer Claims Data to Estimate Changes in Prostate Cancer Screening at the Small-Area Level.
Article in JCO clinical cancer informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeIn 2018, the US Preventive Services Task Force (USPSTF) updated its prostate cancer screening recommendations for men age 55-69 years from grade D, discouraging screening, to grade C, supporting individualized decision making based on clinician judgment and patient preference. Although one study reported increased screening after the 2017 draft recommendation, findings were based on privately insured populations. This study assessed changes in screening after USPSTF revisions in Colorado, examining variation by payer and area-level social determinants of health.
methodsUsing Colorado's All-Payer Claims Database, we included men age 55-69 years with continuous annual enrollment between 2014 and 2023 and measured prostate screening procedures. Negative binomial regression models with population offsets and spline knots in 2016 and 2018 estimated changes in screening, adjusting for age and year, and clustering at the Zip Code Tabulation Area level. Data from 2020 were not used in the model because of pandemic-related disruptions. Analyses were stratified by payer. To assess geographic variation, we estimated random-effects negative binomial models and examined associations between predicted screening changes and the social deprivation index.
resultsIn a sample of over 2 million person-years, 595,107 (27.8%) were screened during the study period. Screening rates increased steadily across all payers, rising from 23.1% in 2014 to 32.1% in 2023, with the largest gains among Medicare Advantage and commercial enrollees. Increases varied geographically, with smaller gains in areas with higher deprivation levels, in particular, areas with poverty, low educational attainment, and crowded housing.
conclusionProstate cancer screening increased after recommendation revisions across all payers, but the magnitudes and trajectories varied. Our results suggest barriers to screening among eligible and insured men associated with socioeconomic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.